Not “due to” in the sense that that’s where the money directly goes, but concerns about slowing medical innovation are one of the big arguments that are raised against reform proposals in the US. In Europe, my understanding is that this is broadly not a concern and few health systems take fully incentivizing new therapies as a design criterion.